SCHEMBL9945684

SCHEMBL9945684

CC(C)CC(C)CCCN

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
NFKB1 P19838 1/20 0.32
HTR2A P28223 1/20 0.31
HRH1 P35367 1/20 0.31
ANPEP P15144 1/20 0.31
ERAP2 Q6P179 1/20 0.31
ERAP1 Q9NZ08 1/20 0.31
CA12 O43570 2/20 0.30
CA1 P00915 2/20 0.30
CA2 P00918 2/20 0.30
CA3 P07451 2/20 0.30
CA4 P22748 2/20 0.30
CA6 P23280 2/20 0.30
CA5A P35218 2/20 0.30
CA7 P43166 2/20 0.30
CA9 Q16790 2/20 0.30
CA14 Q9ULX7 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19901952 1.00 LMNA (0.39) LMNATSHRALDH1A1MAPK1NFKB1
SCHEMBL22215550 0.92 LMNA (0.43) LMNATSHRALDH1A1MAPK1NFKB1
SCHEMBL23978135 0.90 LMNA (0.42) LMNATSHRALDH1A1CA12CA1
SCHEMBL3362217 0.82
SCHEMBL23021103 0.82
SCHEMBL1146663 0.82 LMNA (0.47) LMNATSHRALDH1A1NFKB1HTR2A
SCHEMBL16240597 0.81 ALDH1A1 (0.41) LMNATSHRALDH1A1MAPK1NFKB1
SCHEMBL830510 0.81 LMNA (0.32) LMNAALDH1A1NFKB1HTR2AHRH1
SCHEMBL21011204 0.79 LMNA (0.31) LMNA
SCHEMBL24835043 0.79 RNPEP (0.32) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023212057-A1 COMPOSITIONS OF KINETIC NANOPARTICLES CONTAINING NUCLEIC ACIDS, POLYCATIONS AND LIPIDS THE JOHNS HOPKINS UNIVERSITY (US) 2023-11-02 WO disclosed
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-11 US disclosed
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-11 US disclosed
WO-2023077150-A1 POLYMERS AND NANOPARTICLES FOR INTRAMUSCULAR NUCLEIC ACID DELIVERY THE JOHNS HOPKINS UNIVERSITY (US) 2023-05-04 WO disclosed
US-20230002790-A1 POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
US-20220154219-A1 GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS THE JOHNS HOPKINS UNIVERSITY 2022-05-19 US disclosed
US-20210388196-A1 GENE DELIVERY CARRIER MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-12-16 US disclosed
US-11041069-B2 Gene delivery carrier MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-06-22 US disclosed
WO-2020198145-A1 GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS THE JOHNS HOPKINS UNIVERSITY (US) 2020-10-01 WO disclosed
US-20200140831-A1 TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY THE JOHNS HOPKINS UNIVERSITY 2020-05-07 US disclosed
US-9884118-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERSITY (US) 2018-02-06 US disclosed
US-9884118-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERSITY (US) 2018-02-06 US disclosed
US-9840597-B2 Polyamide-polyolefin copolymers and methods of making them EXXONMOBIL CHEMICAL PATENTS INC. (US) 2017-12-12 US disclosed
US-9777231-B2 Hydrohalogenation of vinyl terminated polymers and their functionalized derivatives for fouling mitigation in hydrocarbon refining processes EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2017-10-03 US disclosed
US-9714393-B2 Ring opening cross metathesis of vinyl terminated polymers and their functionalized derivatives for fouling mitigation in hydrocarbon refining processes EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2017-07-25 US disclosed
US-9663727-B2 Functionalized polymers containing polyamine succinimide for antifouling in hydrocarbon refining processes EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2017-05-30 US disclosed
US-20170143639-A1 NANOCOMPOSITES OF GOLD AND POLYMERS THE JOHNS HOPKINS UNIVERSITY (US) 2017-05-25 US disclosed
US-8562966-B2 End-modified poly(beta-amino esters) and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-10-22 US disclosed
US-20120149630-A1 END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2012-06-14 US disclosed
US-20080242626-A1 End-Modified Poly(beta-amino esters) and Uses Thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149630-A1 END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF PARN, PARG, POLL LMNA 566/4885TSHR 4517/4885ALDH1A1 2664/4885
US-20080242626-A1 End-Modified Poly(beta-amino esters) and Uses Thereof PARN, PARG, POLL LMNA 566/4885TSHR 4517/4885ALDH1A1 2664/4885
US-20170143639-A1 NANOCOMPOSITES OF GOLD AND POLYMERS HNRNPL, HNRNPLL, ACSL3 LMNA 343/4885TSHR 1764/4885ALDH1A1 883/4885
US-11041069-B2 Gene delivery carrier PAICS, PBDC1, BCAT1 LMNA 330/4885TSHR 3794/4885ALDH1A1 2765/4885
US-20210388196-A1 GENE DELIVERY CARRIER PAICS, PBDC1, BCAT1 LMNA 330/4885TSHR 3794/4885ALDH1A1 2765/4885
US-20220154219-A1 GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS PBK, MICA, STAT3 LMNA 3911/4885TSHR 3092/4885ALDH1A1 4160/4885
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy POLRMT, HDGF, PCNP LMNA 2375/4885TSHR 3981/4885ALDH1A1 3433/4885
US-20200140831-A1 TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY POLRMT, HDGF, PCNP LMNA 2375/4885TSHR 3981/4885ALDH1A1 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.